Stock SRT3 SARTORIUS AG
Add to a list
To use this feature you must be a member
Log inSign up

Financials Sartorius AG

Equities

SRT3

DE0007165631

Advanced Medical Equipment & Technology

Market Closed - Xetra
Other stock markets
 11:35:17 2024-04-26 EDT 		5-day change 1st Jan Change
290.2 EUR +2.87% Intraday chart for Sartorius AG +6.85% -12.91%
04-24 SARTORIUS VORZUEGE : Gets a Buy rating from Berenberg ZD
04-23 SARTORIUS VORZUEGE : DZ Bank gives a Sell rating ZD

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 12,508 23,546 37,429 24,078 20,462 17,869 - -
Enterprise Value (EV) 1 13,519 25,430 39,161 26,454 25,394 21,915 21,660 21,273
P/E ratio 83 x 104 x 127 x 37.2 x 111 x 77.7 x 52.4 x 40.8 x
Yield 0.37% 0.21% 0.21% 0.39% 0.22% 0.29% 0.39% 0.46%
Capitalization / Revenue 6.85 x 10.1 x 10.9 x 5.77 x 6.03 x 4.99 x 4.43 x 3.96 x
EV / Revenue 7.4 x 10.9 x 11.4 x 6.34 x 7.48 x 6.12 x 5.37 x 4.72 x
EV / EBITDA 27.3 x 36.7 x 33.3 x 18.8 x 26.4 x 20.4 x 17 x 14.4 x
EV / FCF 89.2 x 93.7 x 85.4 x 125 x 86.4 x 69.4 x 44 x 34.5 x
FCF Yield 1.12% 1.07% 1.17% 0.8% 1.16% 1.44% 2.27% 2.9%
Price to Book 16.1 x 22.4 x 32.3 x 13.9 x 11 x 5.98 x 6.08 x 4.8 x
Nbr of stocks (in thousands) 68,388 68,388 68,416 68,416 68,416 69,029 - -
Reference price 2 190.8 343.6 595.2 369.4 333.2 290.2 290.2 290.2
Announcement Date 20-01-28 21-01-27 22-01-27 23-01-26 24-01-26 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 1,827 2,336 3,449 4,175 3,396 3,582 4,031 4,508
EBITDA 1 495.8 692.2 1,175 1,410 962.7 1,073 1,276 1,482
EBIT 1 398.3 456.1 903.2 1,065 503.9 697.7 889.9 1,067
Operating Margin 21.8% 19.53% 26.18% 25.51% 14.84% 19.47% 22.08% 23.68%
Earnings before Tax (EBT) 1 303.2 446.7 668.4 1,182 385.9 494.4 747.8 950.6
Net income 1 156.7 226.3 318.9 678.1 205.2 209.1 353.8 449
Net margin 8.58% 9.69% 9.25% 16.24% 6.04% 5.84% 8.78% 9.96%
EPS 2 2.300 3.310 4.670 9.920 3.000 3.733 5.537 7.104
Free Cash Flow 1 151.6 271.3 458.6 211.6 293.9 315.7 492.2 616.8
FCF margin 8.3% 11.61% 13.3% 5.07% 8.66% 8.81% 12.21% 13.68%
FCF Conversion (EBITDA) 30.58% 39.19% 39.03% 15% 30.53% 29.44% 38.57% 41.62%
FCF Conversion (Net income) 96.76% 119.89% 143.83% 31.2% 143.23% 150.98% 139.11% 137.38%
Dividend per Share 2 0.7100 0.7100 1.260 1.440 0.7400 0.8485 1.137 1.335
Announcement Date 20-01-28 21-01-27 22-01-27 23-01-26 24-01-26 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2021 Q4 2022 Q1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 1,057 922.3 1,025 1,036 2,060 1,053 1,062 903.2 831.8 810.7 849.8 819.6 844.7 904.2 961.8 - -
EBITDA 1 293.5 308.6 349 348.5 697.5 354 358.9 271.9 245.1 216.7 229.3 234.4 231.4 261 293.9 - -
EBIT 1 214.4 230.6 278.7 276 - 272.4 237.6 178.5 125.4 80 120 122.3 156.5 186 217 - -
Operating Margin 20.29% 25% 27.2% 26.65% - 25.88% 22.38% 19.76% 15.08% 9.87% 14.12% 14.92% 18.52% 20.57% 22.56% - -
Earnings before Tax (EBT) 1 168 69.22 350.6 297.2 - - 252 166.3 156.7 22 40.8 73.1 155.2 179.2 208.1 - -
Net income 1 81.1 23.49 205.6 165.8 - 154.2 152.4 - - 8.6 8.4 36.7 57.07 69.62 94 - -
Net margin 7.67% 2.55% 20.06% 16.01% - 14.65% 14.35% - - 1.06% 0.99% 4.48% 6.76% 7.7% 9.77% - -
EPS 2 1.190 0.3500 3.010 2.420 - 2.250 2.230 1.370 1.390 0.1300 0.1100 0.5400 0.8021 0.9860 1.315 - -
Dividend per Share 2 - 1.260 - - - - 1.440 - 1.440 - 0.7400 - 0.2370 0.2370 0.2370 0.2595 0.2595
Announcement Date 20-07-21 22-01-27 22-04-21 22-07-21 22-07-21 22-10-19 23-01-26 23-04-20 23-07-21 23-10-19 24-01-26 24-04-18 - - - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 1,011 1,884 1,733 2,375 4,932 4,046 3,790 3,404
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 2.04 x 2.721 x 1.475 x 1.684 x 5.123 x 3.773 x 2.97 x 2.297 x
Free Cash Flow 1 152 271 459 212 294 316 492 617
ROE (net income / shareholders' equity) 27% 29.9% 48.3% 40.3% 16.7% 10.8% 12.8% 14.4%
ROA (Net income/ Total Assets) 7.79% 5.98% 6.26% 10.3% 4.05% 2.41% 3.34% 4.34%
Assets 1 2,011 3,783 5,091 6,557 5,072 8,674 10,608 10,347
Book Value Per Share 2 11.90 15.30 18.40 26.60 30.20 48.50 47.70 60.40
Cash Flow per Share 2 5.520 7.480 25.30 10.70 12.50 12.00 13.60 14.70
Capex 1 226 240 407 523 560 442 446 441
Capex / Sales 12.35% 10.29% 11.8% 12.52% 16.48% 12.34% 11.05% 9.79%
Announcement Date 20-01-28 21-01-27 22-01-27 23-01-26 24-01-26 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Sartorius AG

Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
290.2 EUR
Average target price
335.8 EUR
Spread / Average Target
+15.72%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Diagnostic & Testing Equipment

1st Jan change Capi.
SARTORIUS AG Stock Sartorius AG
-12.91% 19.08B
QUIDELORTHO CORPORATION Stock QuidelOrtho Corporation
-46.21% 2.65B
INNER MONGOLIA FURUI MEDICAL SCIENCE CO., LTD. Stock Inner Mongolia Furui Medical Science Co., Ltd.
+18.15% 1.87B
SHANGHAI MICROPORT EP MEDTECH CO., LTD. Stock Shanghai MicroPort EP MedTech Co., Ltd.
-3.12% 1.61B
BIOTAGE AB Stock Biotage AB
+23.78% 1.21B
SHANGHAI AOHUA PHOTOELECTRICITY ENDOSCOPE CO., LTD. Stock Shanghai AoHua Photoelectricity Endoscope Co., Ltd.
-10.69% 1.02B
CONTEC MEDICAL SYSTEMS CO.,LTD Stock Contec Medical Systems Co.,Ltd
-20.89% 905M
REVENIO GROUP OYJ Stock Revenio Group Oyj
-7.14% 716M
VAREX IMAGING CORPORATION Stock Varex Imaging Corporation
-18.10% 682M
CELLAVISION AB Stock CellaVision AB
+4.01% 480M
Medical Diagnostic & Testing Equipment
  1. Stock Market
  2. Equities
  3. SRT3 Stock
  4. Financials Sartorius AG